Evidence since the Sept 22, 2023 episode broadly supports Friedberg’s forecast that this liver‑targeted glycosylated‑antigen (“inverse vaccine”) modality would, within a couple of years, generate specific autoimmune therapeutics that show clinical success and gain traction toward market.

1. Modality and mechanism match the paper he described
   The Nature Biomedical Engineering paper he referenced (“Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses”) from the University of Chicago uses a polymer glycosylated with N‑acetylgalactosamine (pGal) to deliver antigens to the liver, inducing antigen‑specific tolerance and reversing disease in a mouse MS model (EAE) and in other settings. (pubmed.ncbi.nlm.nih.gov) This is exactly the liver‑targeted glycosylated‑antigen modality Friedberg summarized on the podcast.

2. Translation into specific clinical therapeutics for autoimmune disease
   Anokion’s KAN‑101 is a “liver‑targeting glycosylation signature conjugated to a deaminated gliadin peptide” designed to induce immune tolerance to gluten in celiac disease—i.e., a direct clinical implementation of the liver‑targeted glycosylated‑antigen idea for a concrete autoimmune indication. (pubmed.ncbi.nlm.nih.gov) Similarly, ANK‑700 for relapsing‑remitting multiple sclerosis (RRMS) uses a myelin immuno‑domain conjugated to a glycosylation signature to induce antigen‑specific tolerance to myelin autoantigens. (businesswire.com) Both are clear examples of “very specific therapeutics for very specific autoimmune conditions using this approach,” as he predicted.

3. Early clinical success and traction by 2024–2025
   Celiac disease (KAN‑101):

   • Phase 1 (ACeD) in 41 celiac patients showed KAN‑101 was safe and well tolerated, with no serious or dose‑limiting toxicities, and produced dose‑dependent modulation of gluten‑induced IL‑2, reduction of gliadin‑specific T cells, and favorable effects on gut‑homing CD8+ T cells—evidence of antigen‑specific tolerance. (pubmed.ncbi.nlm.nih.gov)
   • On the strength of these data, Anokion advanced KAN‑101 into a global Phase 1b/2 ACeD‑it trial and a separate Phase 2a SynCeD trial, and the drug received FDA Fast Track designation in May 2023, indicating regulatory and clinical “traction.” (celiac.org)
   • In May 2024, updated Phase 1b/2 data again supported safety and biomarker efficacy and emphasized KAN‑101’s “unique liver‑targeting mechanism” and induction of functional tolerance after gluten challenge. (businesswire.com)
   • In January 2025, Anokion reported positive symptom data from the Phase 2 ACeD‑it trial, calling it the first symptomatic clinical proof of concept for KAN‑101 as a disease‑modifying treatment for celiac disease; KAN‑101 reduced multiple gluten‑induced symptoms and celiac‑specific composite patient‑reported outcome measures and remained safe across dose levels. (businesswire.com)
     Collectively, these results constitute clear early clinical success and significant advancement into mid‑stage development within ~1.5 years of the podcast.

   Multiple sclerosis (ANK‑700):

   • The Phase 1 MoveS‑it trial in RRMS completed enrollment by late 2023. Interim reports showed ANK‑700 was safe and well tolerated, with biomarker data suggesting induction of immune tolerance to myelin proteins and bystander suppression to related myelin antigens—mechanistic proof that the liver‑targeted glycosylated‑antigen platform is working in humans. (multiplesclerosisnewstoday.com)
   • In September 2024, Anokion presented full Phase 1 MoveS‑it data, describing ANK‑700 as featuring “a novel myelin immuno‑domain conjugated to a glycosylation signature” and reporting no serious adverse events or MRI evidence of disease worsening, plus evidence of tolerization of myelin‑reactive T cells and bystander suppression. The company characterized these results as clinical proof of concept and positioned ANK‑700 as a potential disease‑modifying RRMS therapy. (businesswire.com)
     This again matches Friedberg’s expectation that the modality would produce promising, disease‑specific autoimmune therapeutics relatively quickly.

4. “Go to market” and stage of development by late 2025
   By November 30, 2025, no inverse‑vaccine/glycosylated‑antigen product has yet been approved or commercially launched; even University of Chicago’s own summaries emphasize that no clinically approved inverse vaccines exist yet and human trials are just beginning. (pme.uchicago.edu) KAN‑101 and ANK‑700 are in Phase 2 and Phase 1/early‑development respectively—short of Phase 3 or market authorization—but they are clearly in active clinical development with positive human data, Fast Track status, and multiple global trials, which in industry usage is a standard part of the “go‑to‑market” trajectory for a new modality. (celiac.org)

5. Assessment relative to the normalized prediction
   The normalized claim was that within a couple of years of 2023, “at least some therapies” based on this liver‑targeted glycosylated‑antigen approach would (a) show clinical success, (b) gain traction, and (c) advance toward market (e.g., into late‑stage development or commercial use).

   • (a) and (b) are clearly satisfied: KAN‑101 and ANK‑700 have produced human safety and mechanistic/clinical‑effect signals, are described by their sponsor and independent publications as showing clinical proof of concept or potential disease‑modifying activity, and have progressed into multiple Phase 2 trials with regulatory Fast Track designation. (pubmed.ncbi.nlm.nih.gov)
   • (c) is partially realized: these drugs have advanced meaningfully along the commercialization path (multi‑national Phase 2 with positive data, platform clearly “productized”), even though they have not yet reached Phase 3 or approval.

Given that Friedberg’s core directional prediction—that this glycosylated, liver‑targeted tolerance approach would rather quickly yield specific autoimmune therapeutics with early clinical success and visible momentum toward the market—has indeed materialized by late 2025, the fairest overall judgment is that his prediction is substantively right, with the caveat that full market approval has not yet occurred.